Search Results
Your search for it matches 15625 pages
Showing 1051 - 1100Survival Benefit With Adjuvant Immunotherapy in Patients With Clear Cell RCC
The phase III KEYNOTE-564 study has reported that adjuvant pembrolizumab provides a significant improvement in overall survival for patients with clear cell renal cell carcinoma at high risk of recurrence after surgery. This study is significant, as it represents the first phase III study to show...
AMBASSADOR: Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma
Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option. The Alliance for Clinical Trials in Oncology announced positive results from the phase III AMBASSADOR (A031501) trial for the adjuvant treatment of patients with localized...
Secondary Cancers May Be Rare in Patients Treated With CAR T-Cell Therapy
The development of any type of secondary cancer following chimeric antigen receptor (CAR) T-cell therapy may be rare, according to a recent study published by Ghilardi et al in Nature Medicine. Background Secondary cancers, including T-cell lymphomas, are known risks of cancer treatments such as...
Expert Point of View: Harry P. Erba, MD, PhD
Harry P. Erba, MD, PhD, Professor of Medicine and Director of the Leukemia Program in the Division of Hematologic Malignancies and Cellular Therapy at Duke University School of Medicine, Durham, North Carolina, told The ASCO Post he was not surprised by one of the key findings reported by Smith et ...
Study Examines Real-World Outcomes With Ivosidenib vs Venetoclax in Acute Myeloid Leukemia
In a comparison of real-world outcomes for two common first-line regimens for acute myeloid leukemia (AML) with mutations in isocitrate dehydrogenase 1 (IDH1), treatment with the IDH1-targeted agent ivosidenib plus a hypomethylating agent was associated with better outcomes than venetoclax plus a...
Study Finds Plant-Rich Foods, Nuts/Seeds May Benefit Childhood Cancer Survivors
A recent study, published by Wang et al in the Journal of Clinical Oncology, conducted as part of the St. Jude Lifetime Cohort (SJLIFE), may provide new insights into how diet may affect aging in adult survivors of childhood cancer. This study, involving 3,322 participants aged 18 to 65, found that ...
Generic Drug Shortages and Essential Cancer Medicines
Decisions regarding the rationing of chemotherapy are commonplace in many countries around the world—including those where patients must pay for chemotherapy out of pocket—and increasingly so in cancer settings that treat both well-off and socioeconomically disadvantaged patients. However, these...
International Collaborative Research Efforts in Cardio-Oncology
At the 2023 Global Cardio-Oncology Symposium (GCOS), international experts explored the ongoing collaborative efforts to improve the cardiovascular health of patients being treated for cancer as well as the bidirectional challenges of translating basic research to clinical care. Focus on Basic and...
Expert Point of View: Daniel Curtis McFarland, DO, MS
Invited discussant of the abstracts on the virtual mind-body fitness program and the BRIDGE intervention from the 2023 ASCO Quality Care Symposium, Daniel Curtis McFarland, DO, MS, of Wilmot Cancer Center, University of Rochester Medical Center, New York, said they highlight the unmet need...
Integrated Medicine and Collaborative Care: Innovations in Cancer Treatment and Mental Health Care
Recent studies by multidisciplinary teams at Memorial Sloan Kettering Cancer Center and Massachusetts General Hospital are illuminating novel ways to address health-care challenges faced by patients with cancer. The research, presented at the 2023 ASCO Quality Care Symposium, highlights the...
NATALEE Trial: Long-Term Results on Ribociclib Combination Therapy in Early-Stage Breast Cancer
Invasive disease–free survival continued to be significantly improved for patients with hormone receptor–positive, HER2-negative, early-stage breast cancer who received the CDK4/6 inhibitor ribociclib plus a nonsteroidal aromatase inhibitor compared with a nonsteroidal aromatase inhibitor alone....
Expert Point of View: Cynthia E. Dunbar, MD
In a press briefing at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, Cynthia E. Dunbar, MD, ASH Secretary and Chief of the Translational Stem Cell Biology Branch, Intramural Research Program of the National Heart, Lung, and Blood Institute, offered her thoughts on...
Expert Point of View: Andrew D. Zelenetz, MD, PhD
Andrew D. Zelenetz, MD, PhD, Medical Director of Quality Informatics at Memorial Sloan Kettering Cancer Center, New York, offered his thoughts on the combination of venetoclax and ibrutinib in the treatment of mantle cell lymphoma, as presented at the 2023 American Society of Hematology (ASH)...
Expert Point of View: Paul J. Hampel, MD
Paul J. Hampel, MD, a hematologist/oncologist at Mayo Clinic, Rochester, Minnesota, underscored the complexity of this arm of the adaptive FLAIR trial, which compared measurable residual disease (MRD)-directed ibrutinib plus venetoclax with standard, fixed-duration, FCR (fludarabine,...
Personalized Ibrutinib-Plus-Venetoclax Therapy: New Treatment Standard for Chronic Lymphocytic Leukemia?
A time-limited approach based on measurable residual disease (MRD) response could signal a potential paradigm shift for front-line treatment of chronic lymphocytic leukemia (CLL), according to data presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition1 and...
Expert Point of View: Ajay K. Nooka, MD, MPH, and Dan Vogl, MD, MSCE
Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology at Emory University, and Dan Vogl, MD, MSCE, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, shared their thoughts on the PERSEUS trial for The ASCO Post. Dr. Nooka noted that ...
Real-World Experience Mirrors PERSEUS Findings
At the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, researchers from Emory University presented a real-world comparison of the largest cohort of patients with newly diagnosed multiple myeloma consecutively treated with either bortezomib, lenalidomide, and dexamethasone ...
PERSEUS: Daratumumab Regimen Significantly Improves Progression-Free Survival in Newly Diagnosed Multiple Myeloma
The addition of the CD38 monoclonal antibody daratumumab to a standard regimen for patients with newly diagnosed transplant-eligible multiple myeloma significantly prolonged progression-free survival vs standard treatment in the phase III PERSEUS trial. The study was reported as a late-breaking...
Use of Direct Oral Anticoagulant Agents in Active Cancer: Meta-Analysis
In a systematic review and meta-analysis reported in JACC: CardioOncology, Fujisaki et al found no significant differences among direct oral anticoagulant agents (DOACs) in the prevention of recurrent venous thromboembolism (VTE) associated with active cancer, whereas significant differences in...
Melanoma Overdiagnoses May Be Rising Among White U.S. Patients
Over 50% of all melanoma diagnoses among White patients in the United States may in fact be overdiagnoses, according to a recent study published by Adamson et al in BMJ Evidence-Based Medicine. Background “Cases of cutaneous melanoma have risen significantly in the [United States] over the last 40...
Study Finds Majority of Patients With Lynch Syndrome Are Not Using Aspirin to Reduce Risk of Colon Cancer
Investigators have found that only a minority of patients with Lynch syndrome may be receiving aspirin as chemopreventive therapy, according to new findings presented by Singhal et al at the 2024 ASCO Gastrointestinal Cancers Symposium (Abstract 19). Background “[Patients] with Lynch syndrome are...
George D. Demetri, MD, FASCO, Earns Lifetime Achievement Award in Medicine From Stanford Medicine Alumni Association
George D. Demetri, MD, FASCO, Director of the Sarcoma Center at Dana-Farber Cancer Institute, was awarded the J.E. Wallace Sterling Lifetime Achievement Award in Medicine from the Stanford Medicine Alumni Association (SMAA). Dr. Demetri, an alumnus of the Stanford University School of Medicine,...
My Breast Cancer Experience Has Led Me to Leverage My Expertise in Human-Centered Design to Transform Patient Care
The road to my breast cancer diagnosis in 2018 was long and tortuous. For 3 years leading up to the diagnosis, I had imaging scans and tissue biopsies every 3 months because of suspicious masses in my breasts. The uncertainty was so destabilizing that I was in a constant state of emotional unrest....
Use of Enzalutamide in Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence
On November 16, 2023, the androgen receptor inhibitor enzalutamide was approved for use in patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.1 Supporting Efficacy Data Approval was based on the EMBARK trial (ClinicalTrials.gov...
The High Cost of Oral Agents for Relapsed and Refractory Multiple Myeloma
Late in 2023, Richardson et al shared the results of a phase I/II clinical trial (ClinicalTrials.gov identifier NCT03374085). They concluded that the “all-oral combination of mezigdomide plus dexamethasone showed promising efficacy in patients with heavily pretreated multiple myeloma.”1 Mezigdomide ...
First-Line Nivolumab Plus Ipilimumab Shows Benefit in Metastatic Colorectal Cancer Subset
In the phase III CheckMate 8HW trial, previously untreated patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer derived significant benefit from an immunotherapy doublet of nivolumab plus ipilimumab in the first-line setting, which...
Expert Point of View: Rory M. Shallis, MD
Rory M. Shallis, MD, Assistant Professor of Medicine (Hematology) at Yale School of Medicine, shared his thoughts on the use of revumenib in histone-lysine N-methyltransferase 2A-rearranged (KMT2A-rearranged) leukemia, as reported in the phase II AUGMENT-101 trial. In an interview with The ASCO...
AUGMENT-101 Trial: Menin Inhibitor Revumenib Shows Activity in KMT2A-Rearranged Acute Leukemia
In heavily pretreated patients with a challenging type of acute leukemia, the menin inhibitor revumenib demonstrated clinically meaningful activity, including high rates of response and measurable residual disease (MRD) negativity, according to the efficacy and safety results of the phase II...
New Director of the University of Hawaii Cancer Center, Naoto T. Ueno, MD, PhD, FACP, Is Also a Two-Time Cancer Survivor
In this installment of The ASCO Post ’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Naoto T. Ueno, MD, PhD, FACP, Director of the University of Hawaii Cancer Center. Along with his duties leading the cancer center, Dr. Ueno leads translational breast cancer research...
Novel Molecular Twin Tool May Improve Precision Medicine Care in Patients With Pancreatic Cancer
The novel artificial intelligence (AI)-based Molecular Twin Precision Oncology Platform may be capable of identifying biomarkers that may outperform the standard test for predicting pancreatic cancer survival, according to a recent study published by Osipov et al in Nature Cancer. Background...
Tackling the Challenges of Oncology Workforce Shortages, Increased Patient Demand, and Rising Costs of Care
In May 2023, The ASCO Post launched a new feature, View From the Top: The Future of Cancer Care Delivery, which explores how leaders in oncology are developing strategies to ensure continued innovative oncology care in an ever-changing health-care environment. In this installment, Guest Editor Jame ...
Novel CAR NK-Cell Therapy May Offer Benefit in Patients With B-Cell Malignancies
A novel chimeric antigen receptor (CAR) natural killer (NK)-cell therapy may be effective at treating patients with relapsed or refractory B-cell malignancies, according to a novel study published by Marin et al in Nature Medicine. Study Methods and Results In the new phase I/II trial, researchers...
Combating Racial and Ethnic Disparities in Precision Medicine for Colorectal Cancer
Investigators may have uncovered molecular evidence of racial disparities in the receipt of precision medicine, according to a recent study published by Yamada et al in npj Precision Oncology. Background Colorectal cancer is the third most common cancer type diagnosed in both male and female...
Novel PI3K Inhibitor as Part of Triplet Improves Outcomes in Hormone Receptor–Positive, HER2-Negative Breast Cancer
The addition of inavolisib to first-line treatment with palbociclib plus fulvestrant more than doubled progression-free survival in patients with recurrent PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced breast cancer, according to a late-breaking primary analysis of the phase III ...
Undocumented Cost-of-Care Discussions: A Missed Opportunity in Cancer Treatment
A recent study underscored the need for integrating cost-of-care conversations in cancer treatment. Results of the population-based analysis, presented at the 2023 ASCO Quality Care Symposium,1 showed that only about 25% of patients with newly diagnosed advanced non–small cell lung cancer (NSCLC)...
DXH9 Depletion May Expose Small Cell Lung Cancer Tumors to Immune System Attack
Researchers may have identified a novel genetic mechanism capable of making small cell lung cancer tumors more susceptible to an attack by the immune system, according to a new study published by Murayama et al in Cancer Discovery. The findings could lead to the development of new therapeutics to...
Medicaid Expansion May Improve Postsurgical Survival Outcomes in Patients With NSCLC
Investigators have found that Medicaid expansion under the Affordable Care Act may be associated with a reduced risk of early mortality following surgical resection in patients with non–small cell lung cancer (NSCLC), according to a recent study published by Nogueira et al in JAMA Network Open. The ...
Obesity and a Precursor of Multiple Myeloma
Patients with obesity may be more likely to have monoclonal gammopathy of undetermined significance, according to a recent study published by Lee et al in Blood Advances. Background Monoclonal gammopathy of undetermined significance—a benign hematologic condition characterized by an abnormal...
Novel Blood Test May Help Distinguish Neuroendocrine Prostate Cancer From Other Subtypes
A novel blood test may accurately detect neuroendocrine prostate cancer and differentiate it from castration-resistant prostate adenocarcinoma, according to a recent study published by Franceschini et al in Cancer Discovery. Background Approximately 10% to 15% of patients with metastatic prostate...
A New Approach to Identifying Consumer Products That Contain Cancer-Causing Chemicals
Researchers may have uncovered a novel strategy to predict whether synthetic chemicals may cause breast cancer by examining their specific traits, according to a recent study published by Kay et al in Environmental Health Perspectives. Background The incidence of breast cancer—the most common...
Novel Risk Model May Personalize Prognosis Prediction in Patients With Multiple Myeloma
Researchers have developed a novel computational model for personalized prognosis prediction in patients with newly diagnosed multiple myeloma, according to a new study published by Maura et al in the Journal of Clinical Oncology. Their model for individualized risk in multiple myeloma, or IRMMa,...
Medical Cannabis: Patterns of Use Among Patients With Cancer
Guest Editor’s Note: Cannabis products are rising in popularity and increasingly used for medical purposes. For appropriate counseling and guidance in an oncology setting, clinicians must understand current cannabis use patterns among patients with cancer. In this article, Nirupa Raghunathan, MD,...
ALL in Adults: Trial Updates and Clinical Considerations for Selecting Consolidation Therapy
Although pediatric patients with acute lymphoblastic leukemia (ALL) have seen a dramatic improvement in long-term survival rates over the past 40 years, from approximately 10% to over 95%, adults aged 29 and older have not experienced the same treatment benefits, with survival rates still below...
Long-Term Follow-up Supports Postneoadjuvant T-DM1 Over Trastuzumab in Early, High-Risk, HER2-Positive Breast Cancer
At a median follow-up of 8.4 years, adjuvant use of ado-trastuzumab emtansine (T-DM1) continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy. These ...
Novel Vaccine May Delay Relapse in KRAS-Mutated Pancreatic and Colorectal Cancers
A novel vaccine may be effective at preventing relapse in patients with KRAS-mutated pancreatic and colorectal cancers, according to a recent study published by Pant et al in Nature Medicine. Background KRAS-mutated cancers make up about 25% of all solid tumors, including 90% of pancreatic cancer...
Attitudes Toward Climate Change May Impact Cancer Screening Behavior
Investigators have discovered that individuals who view climate change as a health threat may be more likely to undergo cancer screening, according to a recent study published by Qian et al in the Journal of the National Cancer Institute. The recent findings supported the development of public...
Atezolizumab Plus Carboplatin in Metastatic Triple-Negative Breast Cancer
Researchers have evaluated the efficacy of atezolizumab in combination with carboplatin in patients with triple-negative breast cancer, according to a recent study published by Lehmann et al in JAMA Oncology. The new findings may help researchers better understand biomarkers of immunotherapy...
Real-World Data Show Impact of Immunotherapy in Populations Underrepresented in Lung Cancer Clinical Trials
New research published by Lee et al in JNCCN—Journal of the National Comprehensive Cancer Network found patients treated with first-line immunotherapy for advanced non–small cell lung cancer (NSCLC) had similar results in terms of overall survival, progression-free survival, and treatment duration, ...
Expert Point of View: Carlos L. Arteaga, MD
Carlos L. Arteaga, MD, commented on the findings of the PREFERABLE-EFFECT trial: “This is a wonderful study about what has been obvious to all of us—exercise improves quality of life. Most oncologists probably recommend it, but not necessarily in the structured and rigorous way this study did. We...
Patients With Advanced Breast Cancer May Gain Multiple Benefits From Exercise as Part of Palliative Care
Although current ASCO guidelines recommend exercise for patients with breast cancer during adjuvant therapy with curative intent, the guidelines state that more study is needed regarding the effects of exercise for patients with metastatic breast cancer. The results of the PREFERABLE-EFFECT trial...
